Pulmokine Overview

  • Founded
  • 2007
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 3

Pulmokine General Information


Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 7 University Place
  • Room B127
  • Rensselaer, NY 12144
  • United States
+1 (518) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pulmokine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 000 Completed Generating Revenue
5. Grant 01-Jan-2017 00000 000 Completed Generating Revenue
4. Grant 01-Jan-2016 00.000 000 Completed Generating Revenue
3. Seed Round 04-Mar-2015 000 000 Completed Generating Revenue
2. Debt - General 01-Oct-2014 Completed Generating Revenue
1. Grant 27-Mar-2014 $1.5M Completed Generating Revenue
To view Pulmokine’s complete valuation and funding history, request access »

Pulmokine Executive Team (5)

Name Title Board Seat Contact Info
Lawrence Zisman Founder, Chief Executive Officer & President
Ron Wolff Ph.D Vice President of Regulatory Affairs and Toxicology
Aaron Waxman MD Scientific Advisor
Rubin Tuder MD Scientific Advisor
To view Pulmokine’s complete executive team members history, request access »

Pulmokine Board Members (2)

Name Representing Role Since
Shreefal Mehta Ph.D Self Board Director 000 0000
To view Pulmokine’s complete board members history, request access »

Pulmokine Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
National Heart, Lung and Blood Institute Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
To view Pulmokine’s complete investors history, request access »